Tumor Mutational Burden as a Predictor of Survival with Durvalumab and/or Tremelimumab Treatment in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

PURPOSE: Biomarkers that predict response to immune checkpoint inhibitors (ICI) in recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) are needed. This retrospective study assessed tumor mutational burden (TMB) and outcomes in the phase II HAWK and CONDOR and phase III EAGLE st...

Descripción completa

Detalles Bibliográficos
Autores principales: Wildsmith, Sophie, Li, Weimin, Wu, Song, Stewart, Ross, Morsli, Nassim, Raja, Rajiv, Zhang, Qu, Ye, Jiabu, He, Philip, Shetty, Jagdish, Yovine, Alejandro, Holoweckyj, Nicholas, Real, Katia, Walker, Jill, Wrona, Magdalena, de los Reyes, Melissa, Barker, Craig, Whiteley, Jessica, Haddad, Robert, Licitra, Lisa, Ferris, Robert, Fayette, Jérôme, Zandberg, Dan P., Siu, Lillian L., Mesía, Ricard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2023
Materias:
Clinical Trials: Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10233352/
https://www.ncbi.nlm.nih.gov/pubmed/36806911
http://dx.doi.org/10.1158/1078-0432.CCR-22-2765

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10233352/
https://www.ncbi.nlm.nih.gov/pubmed/36806911
http://dx.doi.org/10.1158/1078-0432.CCR-22-2765

Ejemplares similares